Progression of gestational syphilis and economic implications of the lack of benzathine penicillin on the Brazilian market

Abstract

This study aimed to demonstrate the growth of gestational and congenital syphilis and the costs of treatment in Brazil. For this analysis, incidence rates and estimated percentage change were calculated, as well as the costs of treatment with penicillins. It was concluded that the costs of dealing with the disease more than quadruple when there is no treatment in the primary phase, whether due to discontinuation of treatment, non-compliance with protocol, or failure to supply the drug.